Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone914-847-7000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$6.71 billion
Profitability
Miscellaneous
Employees7,400
Next Earnings Date11/5/2019 (Confirmed)
OptionableOptionable
Regeneron Pharmaceuticals (NASDAQ:REGN) Frequently Asked Questions
What is Regeneron Pharmaceuticals' stock symbol?
Regeneron Pharmaceuticals trades on the NASDAQ under the ticker symbol "REGN."
How were Regeneron Pharmaceuticals' earnings last quarter?
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) posted its earnings results on Tuesday, August, 6th. The biopharmaceutical company reported $5.29 earnings per share for the quarter, beating the Zacks' consensus estimate of $4.60 by $0.69. The biopharmaceutical company earned $1.93 billion during the quarter, compared to analyst estimates of $1.80 billion. Regeneron Pharmaceuticals had a return on equity of 25.79% and a net margin of 28.59%. The company's quarterly revenue was up 20.3% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $5.45 EPS. View Regeneron Pharmaceuticals' Earnings History.
When is Regeneron Pharmaceuticals' next earnings date?
How can I listen to Regeneron Pharmaceuticals' earnings call?
Regeneron Pharmaceuticals will be holding an earnings conference call on Tuesday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What price target have analysts set for REGN?
17 brokers have issued twelve-month price targets for Regeneron Pharmaceuticals' shares. Their forecasts range from $320.00 to $480.00. On average, they expect Regeneron Pharmaceuticals' stock price to reach $389.40 in the next twelve months. This suggests a possible upside of 27.5% from the stock's current price. View Analyst Price Targets for Regeneron Pharmaceuticals.
What is the consensus analysts' recommendation for Regeneron Pharmaceuticals?
17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regeneron Pharmaceuticals in the last year. There are currently 10 hold ratings, 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Regeneron Pharmaceuticals.
What are Wall Street analysts saying about Regeneron Pharmaceuticals stock?
Here are some recent quotes from research analysts about Regeneron Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Regeneron’s fourth-quarter results were impressive as the company comfortably beat on both the top and the bottom line. Regeneron’s growth driver, Eylea continues to drive sales, and label expansion of the drug into additional indications has further boosted growth. Dupixent too has boosted performance. The company is working to expand Dupixent’s label further in several other indications. This should diversify the company’s revenue base and reduce dependence on Eylea. In September 2018, the FDA approved its immuno-oncology therapy, Libtayo for the treatment of patients with metastatic or locally advanced CSCC who are not candidates for curative surgery or curative radiation. New drug approvals boost growth prospects of the company. Shares have outperformed the industry in the past six months. However, the company is highly dependent on Eylea for growth." (2/8/2019)
- 2. Cantor Fitzgerald analysts commented, "We see potential for the pipeline long-term, but from a stock perspective we see more headwinds than tailwinds over the next 12 months for the base business. We think that concerns around competition will continue to be an overhang over 2019 with late-stage readouts in atopic dermatitis. Although we see some potential near-term catalysts with asthma and nasal polyps, we would like to see the hematology and oncology pipeline story emerge a bit more. Valuation Summary We have a 12-month price target of $415 on REGN shares." (2/6/2019)
- 3. JPMorgan Chase & Co. analysts commented, "REGN today reported in-line 3Q product sales (total rev +$21M; 1%) and a bottom-line beat (+$0.74; 14%) while tightening and lowering OpEx/tax guidance. The 3Q print/call was rather uneventful albeit high on details; Eylea was generally in line with expectations (+7% YoY), and Dupixent/Praluent/Kevzara numbers were known following SNY’s print last Wednesday. With many (not all) 4Q18 clinical/regulatory catalysts in the rear view mirror, we expect investors to focus on ongoing product launches and the robustness of the Eylea franchise. Maintain Neutral." (11/7/2018)
Has Regeneron Pharmaceuticals been receiving favorable news coverage?
Media stories about REGN stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Regeneron Pharmaceuticals earned a media sentiment score of -2.4 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Regeneron Pharmaceuticals.
Who are some of Regeneron Pharmaceuticals' key competitors?
Some companies that are related to Regeneron Pharmaceuticals include Novo Nordisk A/S (NVO), AstraZeneca (AZN), Sanofi (SNY), AbbVie (ABBV), GlaxoSmithKline (GSK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG), Bayer (BAYRY), Zoetis (ZTS), Allergan (AGN), Takeda Pharmaceutical (TAK), Vertex Pharmaceuticals (VRTX) and Shiseido (SSDOY).
What other stocks do shareholders of Regeneron Pharmaceuticals own?
Who are Regeneron Pharmaceuticals' key executives?
Regeneron Pharmaceuticals' management team includes the folowing people:
- Dr. Schleifer Leonard S., Co-Founder, Pres, CEO & Exec. Director (Age 66)
- Dr. George D. Yancopoulos, Founding Scientist, Pres, Chief Scientific Officer & Director (Age 59)
- Mr. Robert E. Landry Jr., Exec. VP of Fin. & CFO (Age 55)
- Mr. Daniel P. Van Plew, Exec. VP and GM of Industrial Operations & Product Supply (Age 46)
- Ms. Marion E. McCourt, Sr. VP & Head of Commercial (Age 59)
Who are Regeneron Pharmaceuticals' major shareholders?
Regeneron Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Hexavest Inc. (0.08%), Pacer Advisors Inc. (0.03%), Gulf International Bank UK Ltd (0.02%), State of Alaska Department of Revenue (0.01%), Intellectus Partners LLC (0.00%) and Crossmark Global Holdings Inc. (0.00%). Company insiders that own Regeneron Pharmaceuticals stock include Christopher R Fenimore, George L Sing, Joseph L Goldstein, Michael S Brown, Neil Stahl, P Roy Vagelos and Sanofi. View Institutional Ownership Trends for Regeneron Pharmaceuticals.
Which major investors are selling Regeneron Pharmaceuticals stock?
REGN stock was sold by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., Stonebridge Capital Management Inc. and Gulf International Bank UK Ltd. Company insiders that have sold Regeneron Pharmaceuticals company stock in the last year include Christopher R Fenimore, Joseph L Goldstein, Neil Stahl, P Roy Vagelos and Sanofi. View Insider Buying and Selling for Regeneron Pharmaceuticals.
Which major investors are buying Regeneron Pharmaceuticals stock?
REGN stock was acquired by a variety of institutional investors in the last quarter, including Pacer Advisors Inc., State of Alaska Department of Revenue, Hexavest Inc., Intellectus Partners LLC, Chesley Taft & Associates LLC and Nelson Van Denburg & Campbell Wealth Management Group LLC. View Insider Buying and Selling for Regeneron Pharmaceuticals.
How do I buy shares of Regeneron Pharmaceuticals?
Shares of REGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Regeneron Pharmaceuticals' stock price today?
One share of REGN stock can currently be purchased for approximately $305.44.
How big of a company is Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals has a market capitalization of $33.55 billion and generates $6.71 billion in revenue each year. The biopharmaceutical company earns $2.44 billion in net income (profit) each year or $19.80 on an earnings per share basis. Regeneron Pharmaceuticals employs 7,400 workers across the globe.View Additional Information About Regeneron Pharmaceuticals.
What is Regeneron Pharmaceuticals' official website?
How can I contact Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals' mailing address is 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY, 10591. The biopharmaceutical company can be reached via phone at 914-847-7000 or via email at [email protected]
MarketBeat Community Rating for Regeneron Pharmaceuticals (NASDAQ REGN)
MarketBeat's community ratings are surveys of what our community members think about Regeneron Pharmaceuticals and other stocks. Vote "Outperform" if you believe REGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
